63897-12-1

Basic information

• Product Name: 2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE
• Synonyms: AURORA KA-3220;2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE;2,4-Dichloro-6-methyl-3-nitropyidine;Zinc02559133;Pyridine,2,4-dichloro-6-Methyl-3-nitro-;2,4-Dichloro-6-Mehtyl-3-nitro-pyridine
• CAS NO: 63897-12-1
• Molecular Formula: C₆H₄Cl₂N₂O₂
• Molecular Weight: 207.01
• Product Categories: Pyridine;Heterocycle-Pyridine series
• Mol File: 63897-12-1.mol
• Article Data: 22

Chemical Properties

• Melting Point: 75 °C
• Boiling Point: 309.982 °C at 760 mmHg
• Flash Point: 141.272 °C
• Appearance: /
• Density: 1.537 g/cm³
• Vapor Pressure: 0.00113mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.47±0.10(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE(63897-12-1)
• EPA Substance Registry System: 2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE(63897-12-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• Hazardous Substances Data: 63897-12-1(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-6-methyl-3-nitropyridine is a chemical compound with the formula C6H4Cl2N2O2. It is a bright yellow crystalline solid that is used in the synthesis of pharmaceuticals and agrochemicals. 2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE is a substituted pyridine derivative, which has a variety of applications including as an intermediate in the production of herbicides and insecticides. It is also used as a building block in the synthesis of pharmaceutical compounds, particularly those with antimicrobial or antifungal properties. 2,4-Dichloro-6-methyl-3-nitropyridine is known to be a skin and eye irritant, and proper safety precautions should be taken when handling this compound.

InChI:InChI=1/C6H4Cl2N2O2/c1-3-2-4(7)5(10(11)12)6(8)9-3/h2H,1H3

Upstream product

• 675-10-5 4-hydroxy-6-methyl-2-pyron 
• 4966-90-9 4-hydroxy-6-methyl-3-nitro-2(1H)-pyridinone 
• 3749-51-7 4-hydroxy-6-methyl-2-pyridone 
• 4966-90-9 2,4-Dihydroxy-6-methyl-3-nitropyridine 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 179056-98-5 3-amino-2,4-dichloro-6-methylpyridine 
• 579489-30-8 4-[1-(1-methoxymethylpropyl)-6-methyl-1H-[1,2,3]triazolo[4,5-c]pyridin-4-ylamino]-3-methylphenol 
• 197801-88-0 [3H]-SN₀₀₃ 
• 870135-17-4 4-chloro-1,6-dimethyl-1H-imidazo[4,5-c]pyridine 
• 870135-16-3 2-chloro-6,N⁴-dimethylpyridine-3,4-diamine 
• 870135-18-5 2-bromo-4-chloro-1,6-dimethyl-1H-imidazo[4,5-c]pyridine 
• 870135-20-9 benzyl-(1,6-dimethyl-2-([1,2,3]triazol-2-yl)-1H-imidazo[4,5-c]pyridin-4-yl)amine 
• 1314946-32-1 (R)-1-[1-(2-cyanobenzyl)-3,5-dimethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-7-yl]piperidin-3-yl tert-butyl carbamate 
• 1314947-51-7 (R)-7-(3-tert-butoxycarbonylaminopiperidin-1-yl)-1-(2-cyanobenzyl)-3-methyl-5-methoxycarbonyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine 
• 1314947-53-9 (R)-1-[1-(2-cyanobenzyl)-3-methyl-5-hydroxymethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl]piperidine-3-carbamic acid tert-butyl ester 
• 1392444-63-1 C₂₆H₃₁N₇O₄ 
• 499127-03-6 4-[2-(ethoxymethyl)-6-methyl-4-phenoxy-1H-imidazo[4,5-c]pyridin-1-yl]butan-1-amine 
• 499127-02-5 tert-butyl 4-[2-(ethoxymethyl)-6-methyl-4-phenoxy-1H-imidazo[4,5-c]pyridin-1-yl]butylcarbamate 
• 499126-99-7 tert-butyl 4-[(6-methyl-3-nitro-2-phenoxypyridin-4-yl)amino]butylcarbamate 

Relevant articles and documents

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitchonodrial disease, fibrosis, and/or cardiomyopathy.

FUSED PYRIDINE DERIVATIVES

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.